Objective Our purpose was to confirm the local drug delivery of a paclitaxel-eluting balloon by percutaneous intervention of single arterial segments or bifurcations of porcine coronary arteries.
Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries Objective Our purpose was to confirm the local drug delivery of a paclitaxel-eluting balloon by percutaneous intervention of single arterial segments or bifurcations of porcine coronary arteries.
Methods Eight domestic pigs were subjected to 2 ¾ 30 s Dior balloon dilatation of the mid left anterior descending, left circumflex and proximal right coronary arteries. Bifurcation intervention was performed in six arteries. The dilated, and the distal and proximal reference segments were prepared for tissue paclitaxel concentration measurement. Tissue samples were harvested at mean 1.5, 12, 24 and 48 h after balloon dilatation and plasma samples were taken at various time points.
Results The tissue paclitaxel concentration of the single dilated segment was at 1.5 h postdilatation 1.82 ± 1.60 mmol/l, which decreased significantly to 0.73 ± 0.27 (P = 0.032), 0.62 ± 0.34 and 0.44 ± 0.31 mmol/l at 12, 24 and 48 h. The bifurcation intervention resulted in 5.10 ± 1.80 mmol/l tissue paclitaxel amount in the main branch, which at 12 h had diminished to 1.41 ± 1.23 mmol/l (P = 0.004). The bifurcation side contained 7.00 ± 4.80 mmol/l paclitaxel at 1.5 h postdilatation, which lowered to 2.72 ± 0.40 mmol/l (P = 0.034). 
Introduction
Stent-based local drug delivery seems to be one of the most promising approaches in the treatment of restenosis and neointimal hyperplasia, but has important limitations -sustained release of cytostatic or cytotoxic drugs, delayed reendothelialization and remaining drug-carrier polymeric matrix on the stent surface, which might induce thrombosis and inflammation [1, 2] .
Nonstent-based local delivery of antiproliferative drugs (dissolved in contrast media or in the form of a drugeluting balloon) may be an attractive treatment mode for coronary lesions designated for 'off-label' use for drug-eluting stents, as in bifurcation lesion or in-stent restenosis [3] [4] [5] . Paclitaxel, a lipophilic drug, is able to penetrate into the arterial wall and bind to the hydrophobic sites on fixed tissue elements, impeding movement of the drug across the arterial wall, resulting in a concentrated antiproliferative effect on the migrating smooth muscle cells after arterial injury. Paclitaxel is known to reduce neointimal hyperplasia by stabilizing the polymerized microtubules of the proliferating smooth muscle cells, inhibiting the cell replication predominantly in the G2/M phase [6] . With paclitaxel dissolved in contrast media used for coronary intervention, Scheller et al. [2] reported an antiproliferative effect in the dilated coronary arterial segments with profoundly inhibited neointimal hyperplasia. The short exposure time of the artery to paclitaxel proved sufficient for its diffusion into the vessel wall, which was confirmed by measurement of the arterial tissue paclitaxel concentration. Speck et al. [7] observed an efficient reduction of neointimal hyperplasia using coated balloon in porcine coronary stenting model, by mounting the stents in a paclitaxel-coated balloon. This report was followed by the first successful use of a paclitaxel-coated balloon in humans, assessing the safety and efficacy of this mode of coronary in-stent restenosis [4] .
The key requirement for such a drug delivery procedure is the rapid uptake of the locally delivered paclitaxel by the vessel wall to achieve growth inhibition. In contrast with drug-eluting stents using a drug-coated balloon, the drug elution is not restricted to the stented-dilated area, which might result in an enhanced protection of segments proximal and distal to the treated lesion.
The aim of our study, therefore, was to confirm the uptake of paclitaxel in the coronary arterial wall after usage of a paclitaxel-eluting balloon in the single coronary arterial segments and bifurcations, by measurement of the tissue paclitaxel concentrations in the dilated arterial wall and the adjacent segments at 1.5, 12, 24 and 48 h postdilation.
Materials and methods

Animal preparation
Eight domestic pigs (weight 18-30 kg) were sedated with 12 mg/kg ketamine hydrochloride, 1 mg/kg xylazine and 0.04 mg/kg atropine after overnight fasting. Loading dose of clopidogrel (300 mg, orally) and aspirin (250 mg, orally) were administered 24 h before the procedure. Following intratracheal intubation, arteriotomies of the right femoral arteries were performed under sterile conditions, and a 6F introduction sheath was inserted [8] .
Administration of 200 IU/kg of heparin sodium was followed by selective angiography of the left and right coronary arteries (RCA), and a guide wire was introduced into the distal part of the left anterior descending (LAD), left circumflex (LCx) and RCA. A Dior balloon catheter (2.75-3.0 mm in diameter, 15 mm in length) (Eurocor, Bonn, Germany) was inserted into the LAD and LCx after the origin of the first major diagonal branches or the proximal RCA. The Dior balloon was inflated for 30 s at 6 atm, the balloon was then deflated and inflation was repeated for 30 s at 6 atm. Coronary angiography confirmed the full contact of the balloon with the vessel wall in each dilatation. Additionally, in six LCx arteries with an obtuse marginalis diameter Z 2 mm on the quantitative angiography, bifurcation interventions were performed: first, the main branch was dilated with a Dior balloon at 6 atm for 2 Â 30 s, then the side branch with a Dior balloon (2 Â 30 s, 6 atm), followed by kissing balloon dilatation with the same Dior balloons. In four arteries, bare metal stents (Genius Megaflex, Eurocor, Bonn, Germany) (3.0 mm in diameter, 15 mm in length) were implanted in the main branch before the final kissing balloon dilatation.
Euthanasia was performed with saturated potassium chloride at 1.5, 12, 24 or 48 h after Dior balloon inflations, the heart was excised, and LAD, LCx and RCA dilated (and stented) coronary arterial segments were taken, cut into proximal, middle and distal parts, with additional proximal and distal reference segments (at least 10 mm proximal or distal from the dilated part) and fresh-frozen in liquid nitrogen for determination of the tissue paclitaxel concentrations. Before tissue preparation, the stents were removed from the main branches.
The experiments were conducted in the Institute of Diagnostics and Oncoradiology, University of Kaposvar, Hungary. 'Principle of laboratory animal care' (NIH publication no. 86-23, revised 1985) and the relevant specific Hungarian laws were followed.
Local drug delivery device
The Dior balloon is a coronary dilation balloon in human use with a balloon surface paclitaxel coating of 3.0 mg/ mm 2 (effective delivery dose of 2.0 mg/mm 2 ). The drug is dissolved by a solubility substance and coated onto the microporous balloon surface structure. During the insertion of the Dior catheter and tracking to the coronary lesion, the three-folded Dior balloon protects the loaded drug from an early wash-off effect.
Measurement of tissue paclitaxel levels
The paclitaxel concentration of plasma, LAD, LCx and RCA were measured by high-performance liquid chromatography (AnaKat Institut für Biotechnologie GmbH, Berlin, Germany, analysis blinded to sample origin). Briefly, after thawing, the tissues were weighed at ambient temperature and, depending on the weights, different volumes of ethanol were added to the samples (sufficient ethanol to cover the tissue completely). The samples were then treated with ultrasound for 40 min. About 200 ml samples were centrifuged.
A calibration line was produced in the range between 50 and 5000 ng/ml. The samples for the calibration line were prepared by dilution of a stock solution with a concentration of 1000 mg/ml. Aliquots of all samples (samples from tissue and calibration line) were transferred into autosampler vials and the same volume of 0.1% formic acid was added. The flow rate of the highperformance liquid chromatography system was 0.2 ml/min through a column of ODS Hypersil (ThermoElectron Corporation, Thermo Scientific, Waltham, Massachusetts, USA), particle size 5 m, pore size 120 Å. The isocratic mobile phase consisted of 70% methanol containing formic acid (0.1%). Paclitaxel was detected by mass spectrometry in multiple reaction-monitoring mode with a transition of paclitaxel from 854 to 105 AMU. The tissue paclitaxel concentration was expressed in mmol/l.
Statistics
The continuous parameters were expressed as mean ± SD of the groups. The values of the measured tissue paclitaxel concentration of the individual arterial segments (proximal, middle and distal) were pooled and the pooled mean values were compared using unpaired t-test. A P value of less than 0.05 was considered to be significant.
The statistical analyses were performed with SPSS for Windows version 11.5.
Results
There was no procedural or postprocedural complication after the use of the Dior balloon for dilatation of the single arteries or bifurcations. The tissue paclitaxel concentration of the single dilated segment 1.5 h postdilatation was 1.82 ± 1.60 mmol/l, which decreased significantly to 0.73 ± 0.27 (P = 0.032), 0.62 ± 0.34 and 0.44 ± 0.31 mmol/l at 12, 24 and 48 h. No differences were observed between the LAD, LCx or RCA as regards the drug uptake on dissection of the segments into proximal, middle and distal parts, the paclitaxel tissue concentration was highest in the middle part of the dilated segments (Fig. 1) . The mean paclitaxel concentration of the reference segments gradually decreased from 0.84 ± 0.99 to 0.34 ± 0.36 mmol/l (P = 0.09), and further to 0.28 ± 0.16 and 0.19 ± 0.18 mmol/l tissue at 1.5, 12, 24 and 48 h postdilatation, respectively (Fig. 1) .
The bifurcation intervention resulted in 5.10 ± 1.80 mmol/l tissue paclitaxel dose in the main branch, which decreased at 12 h to 1.41 ± 1.23 mmol/l (P = 0.004). The bifurcation side branch tissue contained 7.00 ± 4.80 mmol/l paclitaxel at 1.5 h postdilatation, which was decreased to 2.72 ± 0.40 mmol/l (P = 0.034). The highest paclitaxel concentration was measured at the intersection point of the side branch and main branch, with the concentration decreasing to the distal part of the main branch (Fig. 2) . The paclitaxel concentrations of the reference segments were similar to that of the single segment dilatation.
No paclitaxel was found in the peripheral blood at 10, 20, 30 min, 1, 2, 12, 24 and 48 h after Dior balloon dilatation.
Discussion
In this study, we have confirmed the effective local delivery of paclitaxel with a Dior paclitaxel-coated balloon by measuring the arterial wall paclitaxel concentration in single or bifurcation segments in porcine coronary arteries at 1.5, 12, 24 and 48 h postdilatation. Our results indicate diffusion of the paclitaxel into the segments adjacent to the dilatation sites, the measured concentration being much less than that in the dilated segment. Bifurcation intervention through double Dior balloons with a final kissing technique resulted in an approximately two to three-fold tissue paclitaxel concentration in both the main branch and the side branch, indicating efficient 
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Balloon dilatation of a bifurcation of porcine coronary artery (upper). Tissue paclitaxel concentrations at 1.5 and 12 h after balloon dilatation (bottom).
amounts of the drug at the most vulnerable sites of bifurcation lesions.
Although the applied dose of paclitaxel (2.0 mg/mm 2 effective dose on stent surface) on the Dior balloon surface is slightly higher than those used in drug-eluting stents, it was selected as the drug has to overcome the diffusion barriers to gain access to the vascular media during the relatively short exposure. The measured tissue paclitaxel concentration was in the same effective range as published in cell cultures, with equipotent inhibition of coronary artery smooth muscle and endothelial cell migration and proliferation (effective from 56 nmol/l to 50 mmol/l, toxic effect over 100 mmol/l) [9] .
Our results are in accordance with the findings of Speck et al. and Scheller et al. in that, at 15 min or 2 h after the use of 100-200 mg paclitaxel diluted in contrast media, the paclitaxel concentrations in the tissue samples from the LAD and LCx were about 2.89-5.28 mmol/l or 2 mmol/l, respectively, and gradually decreased with time, which amount effectively inhibited the neointimal growth 28 days after stent implantation [2, 10] . Similarly, using a paclitaxel-coated balloon with 1.3 or 2.5 mg paclitaxel/ mm 2 stent surface, the measured percentage of the dose in the vessel wall at 40-60 min after balloon dilatation or stent implantation was 8.7-17.3% which corresponds to a tissue level of approximately 5-10 mmol/l [3] . Additionally, Farb et al. [11] measured lower (0.75 ± 0.30 mg) concentrations in the rabbit iliac artery at 6 h after stenting, but they applied a lower dose (42 mg) in drugeluting stents.
In our experiment, the tissue paclitaxel concentration decreased significantly in the first 12 h after either single or double balloon dilatation. Axel et al. [9] highlighted that paclitaxel has a long-lasting effect after an exposure time of only a few minutes, which makes this lipophilic substance a promising candidate for the local antiproliferative therapy of restenosis.
The potential advantage of the drug delivery balloon is the possibility to use it in bifurcation lesions. In our experiment, the tissue paclitaxel concentration was two to three times higher than that measured after single balloon usage, and decreased to the level of the single balloon dilatation as early at 12 h. Interestingly, both the proximal and distal adjacent segments were also loaded with paclitaxel both in single segments or bifurcations, indicating longitudinal diffusion of the drug along the artery, which might have a beneficial effect in inhibiting edge restenosis.
In contrast with the findings of other groups, in our experiments the plasma concentration of paclitaxel was zero at all time points, suggesting the safety of this application mode.
In conclusion, a short exposure of the coronary artery to paclitaxel by local drug delivery with a coated balloon is sufficient for the attainment of an adequate tissue concentration of paclitaxel, which is known to be efficient in inhibiting neointimal growth in the coronary arteries.
